EU/3/04/220 - orphan designation for treatment of glioma
anti epidermal growth factor receptor antibody h-R3
Orphan
Human
Overview
On 2 September 2004, orphan designation (EU/3/04/220) was granted by the European Commission to Oncoscience AG, Germany, for anti epidermal growth factor receptor antibody h-R3 (cimazumab) for the treatment of glioma.
The sponsorship was transferred to Oncoscience GmbH, Germany, in September 2018.
Key facts
- Active substance
- anti epidermal growth factor receptor antibody h-R3
- Intended use
- Treatment of glioma
- Orphan designation status
- Positive
- EU designation number
- EU/3/04/220
- Date of designation
- Sponsor
Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Germany
Tel. +49 40 300 97 990
E-mail: info@oncoscience.de
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: